Regulatory T cell therapies have shown promise for treating autoimmune diseases and aiding transplantation. We summarize a recent NIAID/HESI-sponsored workshop that addressed key issues in non-clinical and clinical development vital to advancing this immune tolerance paradigm.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. Nature 619, 707–715 (2023).
Wardell, C. M., Boardman, D. A. & Levings, M. K. Nat. Rev. Drug Discov. 24, 93–111 (2025).
Ho, P. et al. Sci. Transl. Med. 16, eadm8859 (2024).
Bader, C. S. et al. Blood Adv. 8, 1105–1115 (2024).
Hefazi, M., Bolivar-Wagers, S. & Blazar, B. R. Int. J. Mol. Sci. 22, 9676 (2021).
Sánchez-Fueyo, A. et al. Am. J. Transplant. 20, 1125–1136 (2020).
Voskens, C. et al. Gut 72, 49–53 (2023).
Zieliński, M. et al. Diabetes Obes. Metab. 24, 1534–1543 (2022).
Bender, C. et al. Sci. Transl. Med. 16, eadn2404 (2024).
Desreumaux, P. et al. Gastroenterology 143, 1207–1217.e1202 (2012).
Sato, Y. et al. Mol. Ther. Methods Clin. Dev. 31, 101150 (2023).
Uenishi, G. I. et al. JCI Insight 9, e171844 (2024).
McGovern, J., Holler, A., Thomas, S. & Stauss, H. J. J. Autoimmun. 132, 102888 (2022).
Chen, P. P. et al. Sci. Transl. Med. 13, eabf5264 (2021).
Kaufman, D. B. et al. Am. J. Transplant. https://doi.org/10.1016/j.ajt.2025.01.044 (2025).
Acknowledgements
HESI, NIAID and the workshop organizing committee (J.A.B., M.D.F., H.L., M.L., G. Nepom, L.P.M., G. Price, J.R., P.R., M.G.R., D.R. and M. Sykes). We would also like to thank the speakers (Supplementary Information, Appendix A) and organizations that contributed content to the workshop.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The event was supported by HESI’s Cell Therapy- Tracking, Circulation and Safety (CT-TRACS) and Immunosafety committees; a grant from Genentech, a member of the Roche Group (Scientific and Research Focused Giving P-19309); as well as donations from the following sponsors: Abata Therapeutics, AbbVie, Alexandria Venture Investments, Amgen, AstraZeneca, Bristol-Myers Squibb, GentiBio, PolTREG S.A., Quell Therapeutics, Sonoma Biotherapeutics and T1D Fund. J.A.B. and H.L. are employees of Sonoma Biotherapeutics and have an equity stake in the company. M.G.R. is an employee of Tr1X and has an equity stake in the company. None of the other authors have conflicts to declare.
Supplementary information
Appendix A:
Invited participants and speakers.
Appendix B:
Treg cell therapy studies.
Rights and permissions
About this article
Cite this article
Bluestone, J.A., Burnett, B.K., Crute, C.E. et al. Regulatory T cell therapies to treat autoimmune diseases and transplant rejection. Nat Immunol 26, 819–824 (2025). https://doi.org/10.1038/s41590-025-02154-2
Published:
Issue date:
DOI: https://doi.org/10.1038/s41590-025-02154-2
